Canadian Arthritis Patient Alliance (CAPA) was offered an opportunity to provide feedback related to Health Canada’s Consultation: Handbook for healthcare professionals on biosimilar biologic drugs. CAPA has a Medical Advisory Committee (MAC), and all of our resources...
Access to the right medicines is an important component in managing arthritis. In Canada, the Patented Medicines Prices Review Board (PMPRB) plays a key role in drug pricing in Canada. On July 1, 2020, the newly amended Patented Medicines Regulations will come into...
